Posted on by Zoology Honour
84 / 100
Powered by Rank Math SEO
SEO Score

Dr. You Zhai | Immunotherapy | Best Researcher Award

Residency at Beijing Tiantan Hospital, Capital Medica, China

You Zhai is a prominent researcher in immunotherapy, specializing in CAR-T cell therapy for glioma and leukemia. Currently pursuing his doctoral studies at the Beijing Neurosurgical Institute, Capital Medical University, under the mentorship of Professor Tao Jiang, he has made significant strides in targeted immunotherapies. His research focuses on the development of CAR-T cell therapies for glioblastoma and other cancers. With extensive experience in molecular neuropathology and genetic engineering, he has contributed to various groundbreaking studies, with notable work on the trogocytosis of CAR molecules and tumor antigen escape. Zhai has published extensively in top-tier journals and holds several national patents related to his research. He is dedicated to improving patient outcomes through innovative therapies, aiming to advance the field of cancer immunotherapy.

Professional Profiles📖

Scopus

Education 🎓

You Zhai began his educational journey at The High School Affiliated to Renmin University of China, completing his studies in 2013. He then pursued a degree in Clinical Medicine at Shanghai Jiao Tong University School of Medicine, graduating in 2018. During his undergraduate years, Zhai was actively involved in research, working under Professor Han L at the Shanghai Institute of Hematology, contributing to the development of CAR-T therapies for leukemia. This experience laid the foundation for his future research focus. Zhai’s academic pursuits continued at the Beijing Neurosurgical Institute, Capital Medical University, where he joined the research team of Professor Tao Jiang to explore CAR-T therapies for glioma. His education has been marked by a strong blend of clinical knowledge and innovative scientific inquiry, leading to groundbreaking discoveries in cancer immunotherapy.

Work Experience💼

You Zhai’s research experience spans several years, with notable contributions to CAR-T cell therapies for both leukemia and glioblastoma. From 2014 to 2016, Zhai worked at the State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, focusing on TanCAR T cells targeting CD19 and CD133 to combat MLL leukemic cells. His undergraduate work led to co-first authorship in the journal Leukemia. In 2018, Zhai joined the Beijing Neurosurgical Institute’s Department of Molecular Neuropathology, where he focused on developing dual-targeted IL7Rα-CAR-T cells against glioblastoma. His involvement in the clinical trial of Tris-CAR-T cells for recurrent glioblastoma (NCT05577091) exemplifies his hands-on approach to research, from lab work to clinical trials. Zhai has actively contributed to multiple national patents, advancing targeted drug and cell therapy research. He is now a key technical member in the “Beijing Engineering Research Center for Targeted Drugs and Cell Therapy of Nervous System Tumors.”

Awards and Honors 🏆

You Zhai’s academic excellence and significant contributions to cancer immunotherapy have earned him several prestigious awards and honors. In 2024, he received the IFIA Best Invention Award at iENA2024 for his innovations in immunotherapy. His research was selected for an oral presentation at EANO2024, a major neuro-oncology conference. Zhai’s work has been recognized by the Wang Zhongcheng Scholarship, awarded in June 2024 for his outstanding academic achievements. He has also gained international recognition, having participated in training programs at esteemed institutions like UBC-BC Children’s Hospital (2016) and UCLA (2014). Additionally, he is a member of the Society for Neuro-Oncology of China, further underscoring his leadership in the field. These awards reflect his ongoing dedication to advancing cancer therapies and the field of immunotherapy.

Skills 💡

You Zhai possesses a diverse set of skills crucial to his research in immunotherapy and cancer treatments. He is proficient in scientific research software such as GraphPad, SPSS, and various molecular biology techniques including Western blotting, flow cytometry, immunohistochemistry, and immunofluorescence. Zhai is also highly skilled in advanced experimental techniques like immunoprecipitation, tissue and organoid slicing, and establishing mouse intracranial xerograph tumor models. Additionally, he is well-versed in scientific achievement translation, clinical trial progress, and protocol preparation, making him an asset to any project from laboratory development to clinical application. His expertise extends to the use of Microsoft Office for presentation creation, as well as Photoshop and other design software for scientific communication. These technical skills, combined with his deep knowledge of molecular neuropathology and cancer immunotherapy, enable Zhai to make significant strides in advancing cancer therapies and improving patient outcomes.

Research Focus 🔬

You Zhai’s primary research focus is the development of CAR-T cell therapies for gliomas and other cancers, particularly glioblastoma, through targeted immunotherapies. His work seeks to address challenges such as tumor resistance to CAR-T cells, antigen escape, and the optimization of immunotherapeutic strategies. Zhai has developed dual-targeted IL7Rα-CAR-T cells aimed at enhancing the antitumor efficacy against glioblastoma by targeting the CD44 and CD133 antigens. His pioneering work on “cellular nibbling” proposes a new theoretical framework to understand short-term tumor immune escape. Zhai’s ongoing clinical trials and collaborations with pharmaceutical companies aim to translate his research findings into effective therapies. Additionally, his research has expanded to include immune checkpoint-based CAR-T cells for brain gliomas. He envisions a future where immunotherapy significantly improves the prognosis of cancer patients, focusing on personalized, more effective treatments for solid tumors like glioblastoma.

Conclusion✅

You Zhai is an outstanding candidate for the Best Researcher Award due to his innovative contributions to cancer immunotherapy, particularly in the development of CAR-T cell therapies for glioblastoma and leukemia. His research not only advances scientific knowledge but has the potential to revolutionize cancer treatment, particularly in the field of immunotherapy. While there are areas for improvement in terms of broader dissemination and long-term outcome studies, his impressive academic achievements, patents, and recognition in the scientific community position him as a highly deserving recipient of the award. His dedication to improving patient prognosis and his pioneering work in immunotherapy make him an exemplary researcher in his field.

Publications Top Notes📚

You Zhai, Guanzhang Li, Changqing Pan, Wei Zhang, Tao Jiang
Title: The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma
Year: 2025
Source: Cancer Letters
Citations: 0 (as of the latest information)
Full Text Status: Open Access

Lele Wu, Zheng Zhao, Yong-jae Shin, Tao Jiang, Vinay B. Tergaonkar
Title: Retraction Note: Tumour microenvironment programming by an RNA–RNA-binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma
Year: 2024
Source: Nature Cell Biology, Volume 26, Issue 6, Pages 1003-1018
Citations: 0 (as of the latest information)

You Zhai | Immunotherapy | Best Researcher Award

You May Also Like